Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Finished Goods: 2011-2017

Historic Finished Goods for Anika Therapeutics (ANIK) over the last 7 years, with Dec 2017 value amounting to $4.7 million.

  • Anika Therapeutics' Finished Goods fell 20.31% to $4.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was $4.6 million, marking a year-over-year decrease of 20.31%. This contributed to the annual value of $4.7 million for FY2017, which is 3.02% up from last year.
  • Anika Therapeutics' Finished Goods amounted to $4.7 million in FY2017, which was up 3.02% from $4.5 million recorded in FY2016.
  • Anika Therapeutics' Finished Goods' 5-year high stood at $4.7 million during FY2017, with a 5-year trough of $2.8 million in FY2013.
  • Its 3-year average for Finished Goods is $4.2 million, with a median of $4.5 million in 2016.
  • Data for Anika Therapeutics' Finished Goods shows a peak YoY spiked of 97.80% (in 2013) over the last 5 years.
  • Over the past 5 years, Anika Therapeutics' Finished Goods (Yearly) stood at $2.8 million in 2013, then grew by 15.98% to $3.2 million in 2014, then increased by 9.30% to $3.5 million in 2015, then grew by 29.64% to $4.5 million in 2016, then increased by 3.02% to $4.7 million in 2017.